HURA TuHURA Biosciences, Inc. stock chart & analysis
Conviction 49HealthcareScan · Fri, Nov 6, 2026TuHURA Biosciences, Inc. (HURA) closed at $1.63 (+1.24%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 39, RS Rating 98, -52.5% from its 52-week high, +115.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
HURA technical analysis
Trend
HURA is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 17.5% below the 50-day ($1.98) and 18.3% below the 200-day ($1.99). The 50-day crossed below the 200-day (a death cross) one session ago. ADX(14) at 19 points to a weak trend — more range than direction. It meets 3 of 8 trend-template criteria.
Momentum
RSI(14) is 39, in the bearish half of its range. MACD crossed below its signal line 4 sessions ago. Its RS Rating of 98 puts its weighted 12-month performance ahead of about 98% of the US market.
Volume and volatility
Volume on the latest session ran 0.4× its 20-day average. It trades about $827,943 a day on average. ATR(14) is $0.1589, 9.8% of price — its typical daily range. On-balance volume is trending down.
Key levels
The chart pattern's support is $1.71 and its resistance $2.23. The 52-week range is $0.4100 to $3.43; price is 52.5% below the high and 297.6% above the low. The VWAP anchored at the 52-week high is $2.32, above price.
Performance
HURA returned -15.5% (1 week), -15.5% (1 month), -24.2% (3 months), -31.5% (6 months), -34.8% (1 year), +115.4% (year to date).
About TuHURA Biosciences, Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Pharmaceutical Preparations · Listed 2024 · 22 employees
Recent news
- TuHURA Biosciences, Inc./NV: New debt obligationSEC EDGAR · Fri, Nov 6, 2026
Congress activity
Disclosed STOCK Act trades in HURA · 3 recent
Insider activity
SEC Form 4 transactions in HURA
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Bianco James A. Chief Executive Officer · Common Stock · 2026-05-28 | Gift | 150K | $0 | 2026-05-28 | 2026-05-29 |
SEC filings
EDGAR filings in HURA · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.